KIMMTRAK
(Tebentafusp)Phase 3Small molecule
KIMMTRAK is one of 129 small molecule programs targeting Cutaneous Melanoma. It is currently in Phase 3.
4
Indications
11
Total Trials
9
Active Trials
128
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Tuoyi
SSun Yat-sen University
Phase 3
KIMMTRAK
IImmunocore Ltd
Phase 3
HX008
BBinhui Biopharmaceutical Co., Ltd.
Phase 3
Isolated Perfusion
NNational Cancer Institute (NCI)
Phase 3
HBI-8000
HHUYABIO International, LLC.
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
High-Dose Recombinant Interferon A-2b
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Uveal Melanoma5 trials
Show 2 more trials
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT06246149·290 enrolled
Melanoma2 trials
Cutaneous Melanoma1 trial
Advanced or Metastatic Solid Tumors1 trial
1 more indication
Regulatory
FDA Approval Timeline[4]
Jan 25, 2022
KIMMTRAK
BLA BLA761228
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tebentafusp. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IImmunocore Ltd